Final Program and Oral Abstracts [International Conference on AIDS (8th: 1992: Amsterdam, Netherlands)]

SESSIONS

MONDAY, 20 JULY 1992 16.15-17.45

SESSION 33
Monday, 20 July 1992
Time: 16.15-17.45
Lecture room: B1
Session title: CLINICAL USE OF DDI/DDC
Oral Abstract
Chairperson: To Be Announced
Abstract #

17.05
SWITCHING FROM AZT TO DDI CAN BE BENEFICIAL MoB 0082
IN AIDS PATIENTS WHO ALREADY HAVE TOLERATED
AZT THERAPY FOR AT LEAST SIX MONTHS:
PRELIMINARY RESULTS OF A RANDOM.
MULTICENTER STUDY ISS-901
Floridia, Marco*; Vella, S.*; Tomino, C.*; Dally, L.G.*;
Sebastiani, G.*; Chiesi, A.*; Agresti, M.G.*; *Istituto
Superiore di Sanita; Rome; ITALY
17.15
DISCUSSANT
Fischl, Margaret; University of Miami; Medical School;
UNITED STATES

16.15
RELATIVE EFFECTS OF ddC OR ddl VERSUS ZDV ON
HEALTH STATUS, FUNCTION, AND DISABILITY IN
ACTG 114 AND 116B/117
Bozzette, Samuel A.*; Kanouse, D.*; Berry, S.*; Duan,
N.*; Downes-Leguin, T.*; Hays, R.*; Pettinelli, C.*;
*University of California; Santa Monica; UNITED
STATES
16.25
NUCLEOSIDE ANALOGUES AND PATTERNS OF
SALIVARY, PANCREATIC AND TOTAL AMYLASE IN
HIV POSITIVE INDIVIDUALS
Sweeney, John*; Valentine, C.B.*; Gompells, M.*;
Pinching, A.J.*; Sherwood, R.**; Deenmamode, J.**;
Moncrieff, K.C.***; *St. Mary's Hospital; London;
UNITED KINGDOM; **King's College Hospital; ***MRC
HIC CTC
16.35
ACTG PROTOCOL 116B/117; CLINICAL OUTCOME
OF A RANDOMIZED DOUBLE BLIND CONTROLLED
STUDY OF DDI AND ZDV
Kahn, James*; Lagakos, S.*; Richman, D.*; Dolin, R.*;
Pettinelli, C.*; Mclaren, C.**; Cross, A.**; Et Al.;
*University of California; San Francisco; UNITED
STATES; ** NIAID and Bristol Myers Squibb; Bethesda
16.45
COMPARATIVE EVALUATION OF AZT AND DDI IN
PREVIOUSLY UNTREATED PATIENTS WITH EARLY OR
ADVANCED ARC: PRELIMINARY RESULTS OF THE
ITALIAN RANDOMIZED MULTICENTER STUDY ISS902
Vella, Stefano*; Florida, M.*; Tomino, C.*; Dally, L.G.*;
Sebastiani, G.*; Fragola, V.*; Chiesi, A.*; *lnstituto
Superiore di Sanita; Roma; ITALY

MoB 0077

NOTES

MoB 0078
MoB 0079
MoB 0080

16.55
A DOUBLE BLIND STUDY OF DDI VS CONTINUED AZT MoB 0081
AMONG HIV+ INDIVIDUALS WITH CD4 COUNTS 200
TO 500/MM3 TREATED WITH AZT FOR AT LEAST SIX
MONTHS
Montaner, Julio S.G.*; Rachlis, A.*; Gill, J.*; Beaulieu,
R.*; Tsoukas, C.*; Fanning, M.*; Cameron, W.*; Et Al.;
*Canadian HIV Trials Network; Vancouver; CANADA

97